171 related articles for article (PubMed ID: 18986288)
1. Spectrum of microbial etiology of community-acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials.
Mandell LA
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S189-92. PubMed ID: 18986288
[TBL] [Abstract][Full Text] [Related]
2. The role of new therapies for severe community-acquired pneumonia.
Restrepo MI; Anzueto A
Curr Opin Infect Dis; 2006 Dec; 19(6):557-64. PubMed ID: 17075331
[TBL] [Abstract][Full Text] [Related]
3. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
4. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.
Niven DJ; Laupland KB
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):69-81. PubMed ID: 19622058
[TBL] [Abstract][Full Text] [Related]
5. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia.
Ramirez J; Aliberti S; Mirsaeidi M; Peyrani P; Filardo G; Amir A; Moffett B; Gordon J; Blasi F; Bordon J
Clin Infect Dis; 2008 Jul; 47(2):182-7. PubMed ID: 18533841
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic testing to establish a microbial cause is helpful in the management of community-acquired pneumonia.
Skerrett SJ
Semin Respir Infect; 1997 Dec; 12(4):308-21. PubMed ID: 9436958
[TBL] [Abstract][Full Text] [Related]
7. Is it possible to blind a trial for community-acquired pneumonia?
Boucher HW
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S210-5. PubMed ID: 18986292
[TBL] [Abstract][Full Text] [Related]
8. Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
Bradley JS; McCracken GH
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S241-8. PubMed ID: 18986297
[TBL] [Abstract][Full Text] [Related]
9. Lower respiratory tract infection and pneumonia in the community.
Macfarlane J
Semin Respir Infect; 1999 Jun; 14(2):151-62. PubMed ID: 10391409
[TBL] [Abstract][Full Text] [Related]
10. Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value.
Murphy TF
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S145-9. PubMed ID: 18986281
[TBL] [Abstract][Full Text] [Related]
11. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
Bratzler DW; Ma A; Nsa W
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
13. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia.
Schouten JA; Prins JM; Bonten MJ; Degener J; Janknegt RE; Hollander JM; Jonkers RE; Wijnands WJ; Verheij TJ; Sachs AP; Kullberg BJ;
Neth J Med; 2005 Sep; 63(8):323-35. PubMed ID: 16186645
[TBL] [Abstract][Full Text] [Related]
14. Management of community-acquired pneumonia by trained family general practitioners.
Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
[TBL] [Abstract][Full Text] [Related]
15. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study.
Ramírez JA;
Semin Respir Crit Care Med; 2005 Dec; 26(6):543-52. PubMed ID: 16388426
[TBL] [Abstract][Full Text] [Related]
16. [Neumonía acquired in the community. Practical guide elaborated by a committee intersocieties].
Luna CM; Calmaggi A; Caberloto O; Gentile J; Valentini R; Ciruzzi J; Clara L; Rizzo O; Lasdica S; Blumenfeld M; Benchetrit G; Famiglietti A; Apezteguia C; Monteverde A;
Medicina (B Aires); 2003; 63(4):319-43. PubMed ID: 14518147
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
19. Impact of guidelines on outcome: the evidence.
Martínez R; Reyes S; Lorenzo MJ; Menéndez R
Semin Respir Crit Care Med; 2009 Apr; 30(2):172-8. PubMed ID: 19296417
[TBL] [Abstract][Full Text] [Related]
20. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
